Details for Patent: 7,169,791
✉ Email this page to a colleague
Which drugs does patent 7,169,791 protect, and when does it expire?
Patent 7,169,791 protects TASIGNA and is included in one NDA.
Protection for TASIGNA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has sixty patent family members in thirty countries.
Summary for Patent: 7,169,791
Title: | Inhibitors of tyrosine kinases |
Abstract: | The invention relates to compounds of formula ##STR00001## wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease. |
Inventor(s): | Breitenstein; Werner (Basel, CH), Furet; Pascal (Thann, FR), Jacob; Sandra (Rantzwiller, FR), Manley; Paul William (Arlesheim, CH) |
Assignee: | Novartis AG (Basel, CH) |
Application Number: | 10/520,359 |
Patent Claim Types: see list of patent claims | Compound; Process; Composition; Use; |
Drugs Protected by US Patent 7,169,791
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | TASIGNA | nilotinib hydrochloride | CAPSULE;ORAL | 022068-003 | Mar 22, 2018 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Novartis | TASIGNA | nilotinib hydrochloride | CAPSULE;ORAL | 022068-002 | Jun 17, 2010 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Novartis | TASIGNA | nilotinib hydrochloride | CAPSULE;ORAL | 022068-001 | Oct 29, 2007 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,169,791
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
United Kingdom | 0215676.8 | Jul 05, 2002 |
United Kingdom | 0229893.3 | Dec 20, 2002 |
United Kingdom | 0215676.8 | Jul 5, 2002 |
PCT Information | |||
PCT Filed | July 04, 2003 | PCT Application Number: | PCT/EP03/07198 |
PCT Publication Date: | January 15, 2004 | PCT Publication Number: | WO20/04/005281 |
International Family Members for US Patent 7,169,791
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 040390 | ⤷ Try a Trial | |||
Austria | 414699 | ⤷ Try a Trial | |||
Australia | 2003249962 | ⤷ Try a Trial | |||
Brazil | 0312464 | ⤷ Try a Trial | |||
Brazil | PI0312464 | ⤷ Try a Trial | |||
Canada | 2491632 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |